Elimination of doxepin isomers from the horse following intravenous application

Abstract

The tricyclic antidepressant doxepin, representing a 5:1 mixture of trans- and cis-isomers, owns tranquilizing properties. This compound has been associated with illicit medication of racing horses, and therefore should be considered in doping control. Because analysis of doxepin in equine body fluids has not been documented in the literature, a highly sensitive analytical method was developed to individually monitor the doxepin isomers in blood and urine of horses by the use of gas chromatography/mass spectrometry. Following a dose of 1 mg doxepin-HCl/kg intravenously (i.v.), both the isomers were quantified for up to 24 h in serum of horses (n=4). The beta-half-lives of the trans- and cis-isomers were 3.5 and 3.1 h, respectively. The ratio of the trans/cis-isomers was found to be constant (4.7:1) during drug elimination and thus corresponded to the original composition of the antidepressant. Up to 12 h following administration low trans-isomer concentrations in an average range of 2-6 ng/mL were detected in urine of each of the horses, while the cis-isomer was only present in two of four horses for up to 8 and 12 h, respectively. In serum, mean trans-isomer concentrations exceeded urine levels maximally 120-fold after 3 h and at least sixfold after 12 h. As serum exhibits considerably higher concentrations of the doxepin isomers as compared with urine, blood of horses is the recommended body fluid when screening for the antidepressant.

A survey on two years of medication regulation in horse races in Iran

“…Many drugs have been used illegally in horse racing and recent examples include the tricyclic antidepressant doxepin (Hagedorn et al. 2001), prothipendyl (Hagedorn et al.…”

“…Many drugs have been used illegally in horse racing and recent examples include the tricyclic antidepressant doxepin (Hagedorn et al 2001), prothipendyl (Hagedorn et al 1996), etorphine (Woods et al 1986), insulin-like growth factor-I and selected IGF binding proteins (De Kock et al 2001), and ketoprofen (Kim et al 2001).…”